Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2013 | 06:55pm CEST

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

To get more information, click here: http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/. There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ligand-pharmaceuticals-lgnd/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE Levi & Korsinsky, LLP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIGAND PHARMACEUTICALS INC
06/22 LIGAND PHARMACEUTICALS : "Prodrug Compounds and Uses Therof" in Patent Applicati..
06/22 LIGAND PHARMACEUTICALS : Patent Issued for Derivatives of Uridine 5'-Cyclophosph..
06/20 LIGAND PHARMACEUTICALS : Partner Melinta Therapeutics Announces U.S. FDA Approva..
06/20 LIGAND PHARMACEUTICALS : Partner Melinta Therapeutics Announces U.S. FDA Approva..
06/06 LIGAND PHARMACEUTICALS : Surface Oncology enters licence agreement to use Ligand..
06/01 LIGAND PHARMACEUTICALS : Enters into Worldwide OmniAb® Platform License Agreemen..
06/01 LIGAND PHARMACEUTICALS INCORPORATED : LGND) Files An 8-K Entry into a Material ..
06/01 LIGAND PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financi..
05/31 LIGAND PHARMACEUTICALS : Announces Aziyo Biologics Acquires Commercial Products ..
05/30 LIGAND PHARMACEUTICALS : Enters Into Worldwide OmniAb® Platform License Agreemen..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/01 Ligand announces Aziyo Biologics acquires commercial products from partner Co..
05/09 Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q1 2017 Results - Earnings..
05/09 Ligand Pharmaceuticals misses by $0.06, misses on revenue
05/08 Notable earnings after Tuesday?s close
05/08 MARINUS PHARMACEUTICALS : A Discarded CNS Gem Ready To Shine In 2017